As the September 30th government funding deadline nears, more than 700 cancer patients, survivors and advocates from every corner of the United States, including Washington, D.C., Guam, and Puerto Rico, are heading to Capitol Hill to make their voices heard. They will ask lawmakers to prioritize cancer research and prevention programs, along with other proven cancer-fighting policies, highlighting the real-life impact these investments have on patients, families and communities nationwide.

Tomorrow, the House Appropriations Committee is scheduled to consider the draft FY26 appropriations bill approved on September 2 nd by the House Appropriations Subcommittee on Labor, Health and Human Services, Education and Related Agencies. The bill includes an increase in funding for cancer research and cancer prevention and control programs.

More than 100 organizations representing millions of patients with serious health conditions and health care professionals sent a letter to Congress expressing their strong support for the Clinical Trial Modernization Act. Introduced in the House of Representatives in May 2025 by Reps. Raul Ruiz (D-CA) and August Pfluger (R-FL), the bipartisan legislation would help remove cost and geographic barriers to patient participation in clinical trials.

A new ACS CAN study released in the Journal of the American Medical Association (JAMA) finds many patients aren’t made aware of the importance of pharmacogenomic (PGx) testing. A form of biomarker testing, PGx testing examines how variations in a patient’s inherited genes may impact how they respond to different drugs and can improve the effectiveness of treatment and reduce the risk of adverse drug reactions.